Metastatic disease, when the cancer has spread to other parts of the body by the blood or lymph system, is generally not curable with current therapy. The study is enrolling 400 women nationwide with advanced breast cancer who have progressed after one or two prior chemotherapy regimens. Participants will be randomized to receive either the combination of Xeloda and rhuMAb VEGF or Xeloda alone. The antibody is given intravenously every three weeks. Xeloda is given by mouth.
Treatment is continued until the cancer begins to grow.
While this trial is testing the effects of an anti-angiogenesis therapy in women with metastatic disease, the ultimate goal is to determine whether this approach could be effective in women with earlier stages of breast cancer.